Ipamorelin is a selective growth hormone secretagogue (GHS) that has drawn considerable attention in peptide research for its targeted and well-tolerated mechanism of action. Unlike earlier GHRPs, Ipamorelin stimulates the release of growth hormone (GH) through specific activation of the ghrelin receptor (GHSR-1a) without significantly influencing cortisol or prolactin levels. This receptor selectivity makes it one of the cleanest and most predictable peptides in GH-related studies. Preclinical and clinical investigations suggest that Ipamorelin may play a valuable role in supporting lean muscle growth, enhancing recovery, improving bone density, and promoting tissue regeneration. Its mild yet sustained GH pulse also positions it as a promising research candidate for age-related decline, metabolic optimization, and injury recovery models. As a next-generation GHRP, Ipamorelin’s clinical potential lies in its unique balance between potency and safety offering a refined tool for exploring endocrine modulation, cellular repair, and performance physiology within controlled scientific settings.